6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1
Wendy Landier(University of Alabama at Birmingham), Smita Bhatia(University of Alabama at Birmingham), Amanda Termuhlen, Lindsey Hageman(Tianjin Chengjian University), Mary V. Relling(St. Jude Children's Research Hospital), F. Lennie Wong(Tianjin Chengjian University), William E. Evans(St. Jude Children's Research Hospital), A. Kim Ritchey(Children's Hospital of Pittsburgh), David S. Dickens(Albert Einstein College of Medicine), Leo Mascarenhas(University of Southern California), Kelly W. Maloney(Children's Hospital Colorado), William L. Carroll(NYU Langone Health), Yanjun Chen(Tianjin Chengjian University), Jacqueline Casillas(University of California, Los Angeles), Heeyoung Kim(City of Hope), Bruce Bostrom(Minnesota West Community & Technical College)
Cited by 4
Related Papers
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
|Cancer Cell|2002|1.9k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k